FDA User Fee Commitments Drive Diagnostics Office Priorities In 2008
This article was originally published in The Gray Sheet
Executive Summary
In vitro diagnostic issues promise to be an active area for FDA and device industry lobbyists this year in response to a laundry list of commitments agreed to by the agency as part of user fee reauthorization legislation
You may also be interested in...
Expanded FDA Lab Oversight May Result In Relaxed Regs For Some Test Kits
FDA is considering changing how it regulates in vitro diagnostic test kits, perhaps down-classifying some kits, as it prepares to assume oversight of laboratory-developed-test services
Expanded FDA Lab Oversight May Result In Relaxed Regs For Some Test Kits
FDA is considering changing how it regulates in vitro diagnostic test kits, perhaps down-classifying some kits, as it prepares to assume oversight of laboratory-developed-test services
FDA Says Final CLIA Waiver Guidance Eases Burdens; Industry Isn’t Satisfied
Final guidelines to companies developing point-of-care diagnostic tests for use in less sophisticated laboratories offer more leeway in clinical trial design than FDA initially proposed